The contribution of donated human embryos suitable for the
production of embryonic stem cells to increase the quality of
life: Selection and preparation of embryos in the Czech
Republic

J 2023

The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic

VENTRUBA, Tomáš, Pavel VENTRUBA, Michal JEŠETA, Jana ŽÁKOVÁ, Eva LOUSOVÁ et. al.

Základní údaje

Originální název

The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic

Autoři

VENTRUBA, Tomáš (203 Česká republika, garant, domácí), Pavel VENTRUBA (203 Česká republika, domácí), Michal JEŠETA (203 Česká republika, domácí), Jana ŽÁKOVÁ (203 Česká republika, domácí), Eva LOUSOVÁ (203 Česká republika, domácí), Igor CRHA (203 Česká republika, domácí), Tereza SOURALOVÁ (203 Česká republika, domácí), Irena KOUTNÁ (203 Česká republika, domácí) a Aleš HAMPL (203 Česká republika, domácí)

Vydání

Advances in Clinical and Experimental Medicine, WROCLAW, WROCLAW MEDICAL UNIV, 2023, 1899-5276

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.100 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130892

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.17219/acem/158777

UT WoS

000931727500001

Klíčová slova anglicky

stem cells; IVF; human; embryo; hESC

Štítky

14110240, 14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 2. 2024 13:01, Mgr. Tereza Miškechová

Anotace

V originále

Background. Human embryonic stem cells (hESCs) have the unique ability to differentiate into any cell type in the human body and to proliferate indefinitely. Cell therapies involving hESC have shown very promising results for the treatment of certain diseases and confirmed the safety of hESC-derived cells for humans. They are used in cell therapy, mainly in targeted therapy of diseases that are currently incurable. Objectives. The aim of this study was the derivation of clinical-grade hESCs usable in drug development, non-native medicine and cell therapy. Materials and methods. Embryos were thawed, cultivated to the blastocyst stage if necessary, and assisted hatching was subsequently performed. Embryoblasts were mechanically isolated using narrow needles. Each line was kept as a separate batch. The derived hESCs were cultured under hypoxic culture conditions (5% O2, 5% CO2, 37°C) in a NutriStem® hPSC XF Medium with a daily medium change. Results. From January 2018 to July 2020, 138 selected clients were asked for consent to donate embryos, of whom 52 did not respond, 19 terminated the storage of their embryos and 29 extended the storage. Only 38 clients (27.5%) agreed to donate embryos for the derivation of hESCs. At the same time, personal communication with clients took place and another 17 embryo donors were recruited. A total of 160 embryos from 55 donors aged 26–42 years were collected. The embryos were frozen at the blastocyst (33.1%) or morula (46.3%) stage. After the preparation of 64 embryos, embryoblasts were isolated and cultured. Finally, 7 hESC lines were obtained, 4 research-grade and 3 clinical-grade, the first in the Czech Republic. Conclusions. We established a current good manufacturing practice (cGMP)-defined xeno-free and feeder-free system for the derivation, culture and banking of clinical-grade hESC lines that are suitable for preclinical and clinical trials. The quality control testing with criteria concerning sterility, safety and characterization according to cGMP ensured the clinical-grade quality of hESC lines.

Návaznosti

MUNI/A/1301/2022, interní kód MU

Název: Zdroje pro tkáňové inženýrství 13

Investor: Masarykova univerzita, Zdroje pro tkáňové inženýrství 13

NV18-08-00412, projekt VaV

Název: Lidské embryonální kmenové buňky pro klinické aplikace: derivace a charakterizace

Investor: Ministerstvo zdravotnictví ČR, Lidské embryonální kmenové buňky pro klinické aplikace: derivace a charakterizace

Citovat

VENTRUBA, Tomáš, Pavel VENTRUBA, Michal JEŠETA, Jana ŽÁKOVÁ, Eva LOUSOVÁ, Igor CRHA, Tereza SOURALOVÁ, Irena KOUTNÁ a Aleš HAMPL. The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic. Advances in Clinical and Experimental Medicine. WROCLAW: WROCLAW MEDICAL UNIV, 2023, roč. 32, č. 8, s. 901-907. ISSN 1899-5276. Dostupné z: https://dx.doi.org/10.17219/acem/158777.

@article{2287417,
   author = {Ventruba, Tomáš and Ventruba, Pavel and Ješeta, Michal and Žáková, Jana and Lousová, Eva and Crha, Igor and Souralová, Tereza and Koutná, Irena and Hampl, Aleš},
   article_location = {WROCLAW},
   article_number = {8},
   doi = {http://dx.doi.org/10.17219/acem/158777},
   keywords = {stem cells; IVF; human; embryo; hESC},
   language = {eng},
   issn = {1899-5276},
   journal = {Advances in Clinical and Experimental Medicine},
   title = {The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic},
   url = {https://advances.umw.edu.pl/en/ahead-of-print/158777/},
   volume = {32},
   year = {2023}
}

TY  - JOUR
ID  - 2287417
AU  - Ventruba, Tomáš - Ventruba, Pavel - Ješeta, Michal - Žáková, Jana - Lousová, Eva - Crha, Igor - Souralová, Tereza - Koutná, Irena - Hampl, Aleš
PY  - 2023
TI  - The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic
JF  - Advances in Clinical and Experimental Medicine
VL  - 32
IS  - 8
SP  - 901-907
EP  - 901-907
PB  - WROCLAW MEDICAL UNIV
SN  - 18995276
KW  - stem cells
KW  - IVF
KW  - human
KW  - embryo
KW  - hESC
UR  - https://advances.umw.edu.pl/en/ahead-of-print/158777/
N2  - Background. Human embryonic stem cells (hESCs) have the unique ability to differentiate into any cell type in the human body and to proliferate indefinitely. Cell therapies involving hESC have shown very promising results for the treatment of certain diseases and confirmed the safety of hESC-derived cells for humans. They are used in cell therapy, mainly in targeted therapy of diseases that are currently incurable. Objectives. The aim of this study was the derivation of clinical-grade hESCs usable in drug development, non-native medicine and cell therapy. Materials and methods. Embryos were thawed, cultivated to the blastocyst stage if necessary, and assisted hatching was subsequently performed. Embryoblasts were mechanically isolated using narrow needles. Each line was kept as a separate batch. The derived hESCs were cultured under hypoxic culture conditions (5% O2, 5% CO2, 37°C) in a NutriStem® hPSC XF Medium with a daily medium change. Results. From January 2018 to July 2020, 138 selected clients were asked for consent to donate embryos, of whom 52 did not respond, 19 terminated the storage of their embryos and 29 extended the storage. Only 38 clients (27.5%) agreed to donate embryos for the derivation of hESCs. At the same time, personal communication with clients took place and another 17 embryo donors were recruited. A total of 160 embryos from 55 donors aged 26–42 years were collected. The embryos were frozen at the blastocyst (33.1%) or morula (46.3%) stage. After the preparation of 64 embryos, embryoblasts were isolated and cultured. Finally, 7 hESC lines were obtained, 4 research-grade and 3 clinical-grade, the first in the Czech Republic. Conclusions. We established a current good manufacturing practice (cGMP)-defined xeno-free and feeder-free system for the derivation, culture and banking of clinical-grade hESC lines that are suitable for preclinical and clinical trials. The quality control testing with criteria concerning sterility, safety and characterization according to cGMP ensured the clinical-grade quality of hESC lines.
ER  -

VENTRUBA, Tomáš, Pavel VENTRUBA, Michal JEŠETA, Jana ŽÁKOVÁ, Eva LOUSOVÁ, Igor CRHA, Tereza SOURALOVÁ, Irena KOUTNÁ a Aleš HAMPL. The contribution of donated human embryos suitable for the production of embryonic stem cells to increase the quality of life: Selection and preparation of embryos in the Czech Republic. \textit{Advances in Clinical and Experimental Medicine}. WROCLAW: WROCLAW MEDICAL UNIV, 2023, roč.~32, č.~8, s.~901-907. ISSN~1899-5276. Dostupné z: https://dx.doi.org/10.17219/acem/158777.

Podrobný výpis o publikaci